
Dr Craig Gedye
Conjoint Associate Professor
School of Medicine and Public Health
Divide and conquer
Proving cancer to be as unique as its sufferers, Dr Craig Gedye’s fastidious, thoughtful and well-executed scientific research is pursuing a tailored approach to patient care, rather than a ‘one-size-fits-none’ mentality.
Cancer, according to Dr Craig Gedye, is like a jungle - dense, confusing, and, at times, terrifying. No two cancers are exactly alike, and this represents the greatest unmet challenge for patients, their doctors and scientists.
“The challenges drive the themes of my research; the complexity and heterogeneity of cancers,” Craig shares.
“One of the most frustrating things in the world is watching a treatment help one patient and then watching it fail completely in another.”
“It’s far from ideal but unfortunately it’s a reality – cancer is different in every person.”
Craig believes that identifying individuals who won’t benefit from particular therapies is just as important as identifying those who will. With no point offering a treatment that will fail, the solution is to find novel opportunities for specific patients.
Spanning the “whole breadth” of tumour biology, Craig’s efforts are concentrated on six, “very challenging” types of cancer.
“I treat people suffering from melanomas, as well as testicular, kidney, prostate, bladder and brain cancers,” he reveals.
“They’re tricky cancers and very hard to treat, but I think they’re the ones that have the greatest gains to be made.”
Because of the focus of his work, Craig is also an “impromptu spokesperson” for “biobanking”.
“When you have a cancer operation, surgeons cut out the tumour and pathologists put it under the microscope to determine its type, aggressiveness and what ought to be done next,” he explains.
“Once this procedure is finished, anything left over is usually discarded.”
“But this is a terrible waste; any of these peoples’ cancers might teach us about that kind of cancer and the best treatment.”
Adopting the simple saying ‘waste not, want not,’ the multitasking scientist is helping to establish systems for its set up and funding in the Hunter region.
“We want to save samples from every patient’s cancer for research, because I believe they’re extremely valuable,” he affirms.
Skin sins and scientific stumbles
Craig’s research career began in 1990, when he undertook a summer studentship between the University of Canterbury and University of Otago in his native New Zealand.
“After doing medicine,” he comments, “I went back to science and started a PhD in the last semester of my oncology training in 2004.”
Comically labelled as “the best of times and the worst of times,” Craig’s candidature sought to tease out notions of complexity and heterogeneity in melanoma. Under the assumption that different cancer cells are more pivotal than others, his findings were “provocative” but “not conclusive.”
“Normally you have to wait your whole professional life to be proven wrong, but I was humbled just six weeks after submitting my thesis,” he laughs.
“It’s a critical lesson – you must listen to the data.”
“I was forced to let go of an idea I’d been nurturing for three and a half years.”
Proceed with caution
Craig relocated to Canada in 2008, undertaking a Postdoctoral Fellowship at the University of Toronto and Princess Margaret Cancer Centre. Aiming to expand upon his original thesis, he went looking for complexity in kidney cancer – this time forewarned and forearmed.
“We thought cancers might be like beehives,” he says. “If you kill off the worker bees, it doesn’t matter because the queen bee will just make more, so in order to kill a person’s cancer, you need to go straight to the source and eliminate her.”
“Sadly though, this concept, called the cancer stem cell hypothesis, proved to be too nice and neat.”
Testing this hypothesis at each step, Craig spent the first half of his overseas stint exploring “problematic experimental biases” in the idea of cancer stem cells.
“If you look at the idea of a queen bee cancer cell through the lens of all these overlooked biases and problems, the whole idea unravels.” This work has recently been published in Scientific Reports.
While at the Princess Margaret Cancer Centre he simultaneously undertook a Clinical Fellowship in melanoma.
“I was on the ground as the new class of cancer drugs, the checkpoint immunotherapy antibodies, came into the clinic,” he recalls.
“It was mind-blowing to see them work so dramatically in some patients.”
Detect and inspect
Craig moved to Australia in February 2014, signing on to pursue a number of related research interests at the Calvary Mater Newcastle, University of Newcastle and Hunter Medical Research Institute. His main mission is to cement a technical, nuanced understanding of kidney cancer.
“It’s a different disease than most might otherwise imagine,” the School of Biomedical Sciences and Pharmacy affiliate acknowledges.
“To go back a bit, in the first few days of foetal development, the embryo will fold itself into three layers of cells – the endoderm, mesoderm and ectoderm.”
“The first layer becomes the surfaces of our body, such as skin and the lining of the gut, the second forms our internal structure like muscle and bone, and the third is our nerves and wiring.”
“Cancers often revert back to the behaviours of these very primitive cells, so while cancers are found in different parts of the body, they will have originated from one of the three layers, and cancer behaviour is loosely related to these layers too.”
“For example, breast, lung, bowel and ovary cancers all grow from the surface layer (the endoderm); and although they have clear differences, these cancers look a bit like each other and respond to similar chemotherapy treatments.”
Once considered a cancer of the surface layer (the endoderm), Craig’s analyses are suggesting kidney cancer is “better thought of” as a cancer from the middle layer and therefore mesenchymal cancer, or a sarcoma. He is similarly arguing that patients with the commonest form of kidney cancer, could benefit from different courses of treatment.
“Clear cell kidney cancers contain ‘skinny’ mesenchymal cells that hunt for new blood supplies, and ‘fat’ cells that are full of lipids that batten down the hatches to survive,” he elaborates.
“I’m wanting to find out what drives each kidney cancer cell to perform each way.”
“If we can somehow exploit the control of this process, we can look to offer up new ideas for treatment.”
Old, new and used-but-still-useful
In the not-so-distant future, Craig is planning to take a closer look at the 3,500 drugs that are currently licenced for use in humans.
“Where kidney cancer is concerned, we’ll see if any come up as useful treatments that control if we get more fat cells and less skinny cells,” he affirms.
“It might then be possible to write a clinical trial to “repurpose” medications.”
“We are expanding the clinical trials we offer patients at Medical Oncology Research at the Calvary Mater Newcastle, including trials for kidney and brain cancers.”
“It’s hard to start our own clinical trials but in my work with the ANZUP Cancer Trials Group, we are able to work with doctors across the country to devise new treatment ideas.”
“Cancer is tough. But it’s a privilege to be able to pit ourselves against cancer in the lab and in the clinic”.
Divide and conquer
Proving cancer to be as unique as its sufferers, Dr Craig Gedye’s fastidious, thoughtful and well-executed scientific research is pursuing a tailored approach t
Career Summary
Biography
My research focuses on complexity in cancer, with a particular interest in understanding "intratumoural heterogeneity". In every patient, every cancer cell is a bit different to every other cancer cell. Some cancer cells seem to be able to spread and cause trouble; others are less aggressive. What determines these differences? Can we exploit them to target cancer cells that are behaving differently?
Between different patients, cancers that come from the same organ can behave completely differently, and treatments that help one patient fail the next. Why is this? Why does a cancer lie dormant, then come back? Why does treatment not work in some patients, or work for a time, then fail?
These questions are incredibly important, as we seek to find the treatments that work best for each individual patient. We will do this by using existing treatments more cleverly, as well as by discovering new treatments.
Qualifications
- PhD (Medicine Denistry & Health Sciences), University of Melbourne
- Bachelor of Science (Chemistry)(Honours), University of Canterbury - New Zealand
- Bachelor of Medicine, Bachelor of Surgery, University of Otago - New Zealand
Keywords
- Biobanking
- Cancer
- Cancer biology
- Cancer immunotherapy
- Cancer stem cells
- Cell biology
- Clinical trials
- Epigenetic heterogeneity
- Epithelial-mesenchymal transition
- Glioblastoma
- Medical oncology
- Melanoma
- Phenotypic plasticity
- Prostate cancer
- Renal cell carcinoma
Fields of Research
Code | Description | Percentage |
---|---|---|
111204 | Cancer Therapy (excl. Chemotherapy and Radiation Therapy) | 25 |
111201 | Cancer Cell Biology | 50 |
111209 | Solid Tumours | 25 |
Professional Experience
Professional appointment
Dates | Title | Organisation / Department |
---|---|---|
28/5/2016 - 30/11/2017 | Conjoint Senior Lecturer | The University of Newcastle - Faculty of Health and Medicine Australia |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Journal article (61 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2020 |
Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, et al., 'Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial', Annals of Oncology, 31 1553-1560 (2020) © 2020 European Society for Medical Oncology Background: This multicentre, randomised, double-blinded, placebo-controlled, phase II/III trial aimed to evaluate an oral THC:CBD (te... [more] © 2020 European Society for Medical Oncology Background: This multicentre, randomised, double-blinded, placebo-controlled, phase II/III trial aimed to evaluate an oral THC:CBD (tetrahydrocannabinol:cannabidiol) cannabis extract for prevention of refractory chemotherapy-induced nausea and vomiting (CINV). Here we report the phase II component results. Patients and methods: Eligible patients experienced CINV during moderate-to-high emetogenic intravenous chemotherapy despite guideline-consistent antiemetic prophylaxis. Study treatment consisted of one cycle of 1¿4 self-titrated capsules of oral THC 2.5 mg/CBD 2.5 mg (TN-TC11M) three times daily, from days -1 to 5, and 1 cycle of matching placebo in a crossover design, then blinded patient preference for a third cycle. The primary end point was the proportion of participants with complete response during 0¿120 h from chemotherapy. A total of 80 participants provided 80% power to detect a 20% absolute improvement with a two-sided P value of 0.1. Results: A total of 81 participants were randomised; 72 completing two cycles were included in the efficacy analyses and 78 not withdrawing consent were included in safety analyses. Median age was 55 years (range 29¿80 years); 78% were female. Complete response was improved with THC:CBD from 14% to 25% (relative risk 1.77, 90% confidence interval 1.12¿2.79, P = 0.041), with similar effects on absence of emesis, use of rescue medications, absence of significant nausea, and summary scores for the Functional Living Index-Emesis (FLIE). Thirty-one percent experienced moderate or severe cannabinoid-related adverse events such as sedation, dizziness, or disorientation, but 83% of participants preferred cannabis to placebo. No serious adverse events were attributed to THC:CBD. Conclusion: The addition of oral THC:CBD to standard antiemetics was associated with less nausea and vomiting but additional side-effects. Most participants preferred THC:CBD to placebo. Based on these promising results, we plan to recruit an additional 170 participants to complete accrual for the definitive, phase III, parallel group analysis. Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12616001036404; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370473&isReview=true.
|
||||||||||
2020 |
Bouche G, Gedye C, Meheus L, Pantziarka P, 'Drug repurposing in oncology.', Lancet Oncol, 21 e542 (2020)
|
||||||||||
2020 |
Davis JS, Ferreira D, Paige E, Gedye C, Boyle M, 'Infectious complications of biological and small molecule targeted immunomodulatory therapies', Clinical Microbiology Reviews, 33 1-117 (2020) [C1] © 2020 American Society for Microbiology. The past 2 decades have seen a revolution in our approach to therapeutic immunosuppression. We have moved from relying on broadly active ... [more] © 2020 American Society for Microbiology. The past 2 decades have seen a revolution in our approach to therapeutic immunosuppression. We have moved from relying on broadly active traditional medications, such as prednisolone or methotrexate, toward more specific agents that often target a single receptor, cytokine, or cell type, using monoclonal antibodies, fusion proteins, or targeted small molecules. This change has transformed the treatment of many conditions, including rheumatoid arthritis, cancers, asthma, and inflammatory bowel disease, but along with the benefits have come risks. Contrary to the hope that these more specific agents would have minimal and predictable infectious sequelae, infectious complications have emerged as a major stumbling block for many of these agents. Furthermore, the growing number and complexity of available biologic agents makes it difficult for clinicians to maintain current knowledge, and most review articles focus on a particular target disease or class of agent. In this article, we review the current state of knowledge about infectious complications of biologic and small molecule immunomodulatory agents, aiming to create a single resource relevant to a broad range of clinicians and researchers. For each of 19 classes of agent, we discuss the mechanism of action, the risk and types of infectious complications, and recommendations for prevention of infection.
|
||||||||||
2020 |
Afrin F, Chi M, Eamens AL, Duchatel RJ, Douglas AM, Schneider J, et al., 'Can hemp help? Low-THC cannabis and non-THC cannabinoids for the treatment of cancer', Cancers, 12 (2020) [C1]
|
||||||||||
2020 |
Yoon J-Y, Gedye C, Paterson J, Ailles L, 'Stem/progenitor cell marker expression in clear cell renal cell carcinoma: a potential relationship with the immune microenvironment to be explored', BMC CANCER, 20 (2020) [C1]
|
||||||||||
2020 |
Gedye C, Sachchithananthan M, Leonard R, Jeffree RL, Buckland ME, Ziegler DS, et al., 'Driving innovation through collaboration: Development of clinical annotation datasets for brain cancer biobanking', Econometrics Journal, 23 31-37 (2020) [C1] © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. A ... [more] © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. A key component of cancer research is the availability of clinical samples with appropriately annotated clinical data. Biobanks facilitate research by collecting/storing various types of clinical samples for research. Brain Cancer Biobanking Australia (BCBA) was established to facilitate the networking of brain cancer biobanking operations Australia-wide. Maximizing biospecimen utility in a networked biobanking environment requires the standardization of procedures and data across different sites. The aim of this research was to scope and develop a recommended clinical annotation dataset both for pediatric and adult brain cancer biobanks. Methods: A multidisciplinary working group consisting of members from the BCBA Consortium was established to develop clinical dataset recommendations for brain cancer biobanks. A literature search was undertaken to identify any published clinical dataset recommendations for brain cancer biobanks. An audit of data items collected and stored by BCBA member biobanks was also conducted to survey current clinical data collection practices across the BCBA network. Results: BCBA has developed a clinical annotation dataset recommendation for pediatric and adult brain cancer biobanks. The clinical dataset recommendation has 5 clinical data categories: demographic, clinical and radiological diagnosis and surgery, neuropathological diagnosis, patient treatment, and patient follow-up. The data fields have been categorized into 1 of 3 tiers; essential, preferred, and comprehensive. This enables biobanks and researchers to prioritize appropriately where resources are limited. Conclusion: This dataset can be used to guide the integration of data from multiple existing biobanks for research studies and for planning prospective brain cancer biobanking activities.
|
||||||||||
2019 |
Fradgley EA, Chong SE, Cox ME, Gedye C, Paul CL, 'Patients experiences and preferences for opt-in models and health professional involvement in biobanking consent: A cross-sectional survey of Australian cancer outpatients', Asia-Pacific Journal of Clinical Oncology, 15 31-37 (2019) [C1] © 2018 John Wiley & Sons Australia, Ltd Background: Many biobanks rely upon patients¿ willingness to donate biospecimens and healthcare professionals to initiate opt-in cons... [more] © 2018 John Wiley & Sons Australia, Ltd Background: Many biobanks rely upon patients¿ willingness to donate biospecimens and healthcare professionals to initiate opt-in consent processes. This study explored if: (1) patients accept opt-in or opt-out consent models with varying levels of professional involvement; (2) professionals discuss participation with specific patient groups; and (3) this discussion is associated with patient knowledge of biobanking processes. Methods: Outpatients completed surveys at a tertiary cancer center in New South Wales, Australia. Eligible participants were English-speaking adults who recently had cancer-related surgery. Participants completed 27 questions exploring acceptable consent models, biobanking experiences, knowledge, and willingness. Logistic regression and chi-square tests examined differences in the characteristics and knowledge of participants who were offered the opportunity to participate versus those who were not. Results: A total of 113 outpatients participated (97% response). Most participants (92%) found opt-out, patient-initiated consent acceptable; however, high acceptability was reported for all models except for opt-in, patient-initiated consent (58%). University or technical qualifications (P = 0.001) was associated with increased odds (OR¿=¿4.5) of being offered biobanking. The majority did not know what occurred to samples after surgery (59.3%) or pathology review (81.4%) and ability to answer these questions was associated with discussion of participation (P¿<¿0.001). Of the few outpatients who discussed biobanking with their doctor (29%), all consented. Conclusion: Professional-initiated, opt-in consent resulted in a few educated patients being approached; greater professional initiation of consent would be fruitful as most patients were willing to participate if asked. However, other consent approaches minimizing professional involvement were as acceptable to participants warranting further consideration.
|
||||||||||
2019 |
Rowe CW, Faulkner S, Paul JW, Tolosa JM, Gedye C, Bendinelli C, et al., 'The precursor for nerve growth factor (proNGF) is not a serum or biopsy-rinse biomarker for thyroid cancer diagnosis.', BMC endocrine disorders, 19 128 (2019) [C1]
|
||||||||||
2019 |
Rowe CW, Dill T, Faulkner S, Gedye C, Paul JW, Tolosa JM, et al., 'The precursor for nerve growth factor (ProNGF) in thyroid cancer lymph node metastases: Correlation with primary tumour and pathological variables', International Journal of Molecular Sciences, 20 1-13 (2019) [C1]
|
||||||||||
2019 |
Peters S, Clézardin P, Márquez-Rodas I, Niepel D, Gedye C, 'The RANK RANKL axis: an opportunity for drug repurposing in cancer?', Clinical and Translational Oncology, 21 977-991 (2019) [C1]
|
||||||||||
2018 | Gedye C, 'The diverse landscape of genitourinary cancer immunotherapy', Cancer Forum, 42 29-39 (2018) [C1] | ||||||||||
2018 |
Almazi JG, Pockney P, Gedye C, Smith ND, Hondermarck H, Verrills NM, Dun MD, 'Cell-Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer.', Proteomics. Clinical applications, 12 e1700121 (2018) [C1]
|
||||||||||
2018 |
Fradgley EA, Chong SE, Cox ME, Paul CL, Gedye C, 'Enlisting the willing: A study of healthcare professional initiated and opt-in biobanking consent reveals improvement opportunities throughout the registration process', European Journal of Cancer, 89 36-41 (2018) [C1] © 2017 The Authors Biobanking consent processes should accord with patients' preferences and be offered in a consistent and systematic manner. However, these aims can be diff... [more] © 2017 The Authors Biobanking consent processes should accord with patients' preferences and be offered in a consistent and systematic manner. However, these aims can be difficult to achieve under healthcare professionals' (HCPs) time-constrained workflows, resulting in low participation rates. This current perspective provides a brief overview of HCP involvement in consent and reports new data on participant attrition at each step of the biobanking consent process as experienced by 113 patients at an Australian tertiary cancer centre. To determine attrition in this HCP-driven consent process, we reviewed medical records for the following events: inclusion of biobanking consent forms; visible patient and HCP signatures; consent status selected (decline or accept) and specimen registration with local biobank. Accessible medical records revealed the following data: 75 of 85 records included viewable forms; 22 of 85 records included patient and 19 of 85 included HCP signatures; 15 of 85 records included signed and completed forms and 3 of 85 had samples banked with annotated clinical data. We compared these data with self-reported experiences of being approached to participate by HCPs. Of the 15 participants (17.6%) who successfully completed consent, only five could recall being asked and providing consent. The low enrolment rate is a considerable lost opportunity because most patients (59%) who were not asked to participate indicated they would have consented if asked. Furthermore, in comparing self-reported experiences with medical records, we believe cancer patients' preferences for participation are mismatched with actual biobanking enrolment, which has considerable attrition at each step in the consent process.
|
||||||||||
2017 |
Rowe CW, Paul JW, Gedye C, Tolosa JM, Bendinelli C, McGrath S, Smith R, 'Targeting the TSH receptor in thyroid cancer', Endocrine-Related Cancer, 24 R191-R202 (2017) [C1] © 2017 Society for Endocrinology Printed in Great Britain. Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The exis... [more] © 2017 Society for Endocrinology Printed in Great Britain. Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid-stimulating hormone receptor (TSHR) targeting in the post-surgical management of differentiated thyroid cancer using levothyroxine and recombinant human thyroid-stimulating hormone (TSH) is well understood. However, in an era of personalized medicine, and with an increasing awareness of the risk profile of longstanding pharmacological hyperthyroidism, it is imperative clinicians understand the molecular basis and magnitude of benefit for individual patients. Furthermore, TSHR has been recently re-conceived as a selective target for residual metastatic thyroid cancer, with pilot data demonstrating effective targeting of nanoparticles to thyroid cancers using this receptor as a target. This review examines the evidence for TSHR signaling as an oncogenic pathway and assesses the evidence for ongoing TSHR expression in thyroid cancer metastases. Priorities for further research are highlighted.
|
||||||||||
2017 |
Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, et al., 'An Immune Atlas of Clear Cell Renal Cell Carcinoma', Cell, 169 736-749.e18 (2017) [C1] © 2017 The Author(s) Immune cells in the tumor microenvironment modulate cancer progression and are attractive therapeutic targets. Macrophages and T¿cells are key components of t... [more] © 2017 The Author(s) Immune cells in the tumor microenvironment modulate cancer progression and are attractive therapeutic targets. Macrophages and T¿cells are key components of the microenvironment, yet their phenotypes and relationships in this ecosystem and to clinical outcomes are ill defined. We used mass cytometry with extensive antibody panels to perform in-depth immune profiling of samples from 73 clear cell renal cell carcinoma (ccRCC) patients and five healthy controls. In 3.5 million measured cells, we identified 17 tumor-associated macrophage phenotypes, 22 T¿cell phenotypes, and a distinct immune composition correlated with progression-free survival, thereby presenting an in-depth human atlas of the immune tumor microenvironment in this disease. This study revealed potential biomarkers and targets for immunotherapy development and validated tools that can be used for immune profiling of other tumor types.
|
||||||||||
2016 |
Khoja L, Atenafu EG, Ye Q, Gedye C, Chappell M, Hogg D, et al., 'Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma', Oncology Letters, 11 1581-1585 (2016) [C1] © 2016, Spandidos Publications. All rights reserved. Approved by the Food and Drug Administration in 2011, the anti-cytotoxic T-lymphocyte-associated protein 4 checkpoint inhibito... [more] © 2016, Spandidos Publications. All rights reserved. Approved by the Food and Drug Administration in 2011, the anti-cytotoxic T-lymphocyte-associated protein 4 checkpoint inhibitor ipilimumab has delivered a survival benefit of =3 years in a subset of metastatic melanoma patients. After participating in the registration trial, patients were treated with this agent in routine practice. Toxicity and efficacy of agents in ¿real world¿ settings may differ from trials. The present study aimed to evaluate, with respect to toxicity and outcome, all patients treated with ipilimumab to date at the Princess Margaret Hospital (Toronto, Canada). Patients treated with ipilimumab between 2008 and 2013 were identified, and patient characteristics (age, gender, tumour burden, oncogenic mutation status, number of treatments received and toxicities from treatment) were collected. Progression-free survival (PFS) and overall survival (OS) were calculated from the commencement of ipilimumab treatment. Associations between clinical characteristics and outcome or toxicity were assessed. Between 2008 and 2013, 129 patients with metastatic cutaneous melanoma were treated. Since, during this period, ipilimumab was approved in the second line setting, ipilimumab was delivered in the second or subsequent line in all patients, and 70% did not receive any further anticancer therapy. Immune-related toxicities were observed, the onset of which varied from 1 to 162 days. The majority resolved within 6 weeks of the final treatment, with the exception of endocrinopathies and bowel related toxicity. The median PFS and OS were 2.83 and 8.44 months, respectively. No pre-treatment factor independently predicted toxicity. The number of infusions (4 vs. =3) and presence of toxicity were significantly associated with superior survival. The onset of toxicity secondary to ipilimumab could occur later than previously reported. Toxicities were manageable, but required long-term vigilance.
|
||||||||||
2016 |
Gedye C, Sirskyj D, Lobo NC, Meens J, Hyatt E, Robinette M, et al., 'Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma', Scientific Reports, 6 (2016) [C1] Rare cancer stem cells (CSC) are proposed to be responsible for tumour propagation and re-initiation and are functionally defined by identifying tumour-initiating cells (TICs) usi... [more] Rare cancer stem cells (CSC) are proposed to be responsible for tumour propagation and re-initiation and are functionally defined by identifying tumour-initiating cells (TICs) using the xenotransplantation limiting dilution assay (LDA). While TICs in clear cell renal cell carcinoma (ccRCC) appeared rare in NOD/SCID/IL2R¿ 3 -/- (NSG) mice, xenografts formed more efficiently from small tumour fragments, indicating the LDA underestimated ccRCC TIC frequency. Mechanistic interrogation of the LDA identified multiple steps that influence ccRCC TIC quantitation. For example, tissue disaggregation destroys most ccRCC cells, common assays significantly overestimate tumour cell viability, and microenvironmental supplementation with human extracellular factors or pharmacological inhibition of anoikis increase clonogenicity and tumourigenicity of ccRCC cell lines and primary tumour cells. Identification of these previously uncharacterized concerns that cumulatively lead to substantial underestimation of TICs in ccRCC provides a framework for development of more accurate TIC assays in the future, both for this disease and for other cancers.
|
||||||||||
2016 |
Gedye C, Fleming J, 'Forsaking cures for cancer: why are we discarding the tumour biospecimens of most patients?', MEDICAL JOURNAL OF AUSTRALIA, 204 297-298 (2016) [C1]
|
||||||||||
2016 |
Chia PL, Gedye C, Boutros PC, Wheatley-Price P, John T, 'Current and Evolving Methods to Visualize Biological Data in Cancer Research', JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 108 (2016) [C1]
|
||||||||||
2016 |
Gedye C, Fleming J, 'Forsaking cures for cancer: why are we discarding the tumour biospecimens of most patients?', MEDICAL JOURNAL OF AUSTRALIA, 204 297-+ (2016)
|
||||||||||
2016 |
Lobo NC, Gedye C, Apostoli AJ, Brown KR, Paterson J, Stickle N, et al., 'Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: Clinically relevant models for research and personalized medicine', BMC Cancer, 16 (2016) [C1]
|
||||||||||
2016 |
Gedye C, Cardwell T, Dimopoulos N, Tan BS, Jackson H, Svobodová S, et al., 'Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro', Stem Cell Reviews and Reports, 12 156-161 (2016) [C1] © 2015, Springer Science+Business Media New York. Cancer cell lines can be useful to model cancer stem cells. Infection with Mycoplasma species is an insidious problem in mammalia... [more] © 2015, Springer Science+Business Media New York. Cancer cell lines can be useful to model cancer stem cells. Infection with Mycoplasma species is an insidious problem in mammalian cell culture. While investigating stem-like properties in early passage melanoma cell lines, we noted poorly reproducible results from an aliquot of a cell line that was later found to be infected with Mycoplasma hyorhinis. Deliberate infection of other early passage melanoma cell lines aliquots induced variable and unpredictable effects on expression of putative cancer stem cell markers, clonogenicity, proliferation and global gene expression. Cell lines established in stem cell media (SCM) were equally susceptible. Mycoplasma status is rarely reported in publications using cultured cells to study the cancer stem cell hypothesis. Our work highlights the importance of surveillance for Mycoplasma infection while using any cultured cells to interrogate tumor heterogeneity.
|
||||||||||
2016 |
Khoja L, Kibiro M, Metser U, Gedye C, Hogg D, Butler MO, et al., 'Patterns of response to anti-PD-1 treatment: An exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients', British Journal of Cancer, 115 1186-1192 (2016) [C1] © 2016 Cancer Research UK. Background:Radiological assessment of response to checkpoint inhibitors remains imperfect. We evaluated individual lesion and inter-patient response by ... [more] © 2016 Cancer Research UK. Background:Radiological assessment of response to checkpoint inhibitors remains imperfect. We evaluated individual lesion and inter-patient response by response evaluation (RECIST) 1.1, immune-related response criteria (irRC), CHOI and modified CHOI (mCHOI) and correlated response with overall survival (OS).Methods:Thirty-seven patients with 567 measurable lesions treated with pembrolizumab in the Keynote 001 trial were studied. Association of response with OS was determined.Results:Response varied according to site; lung lesions had the highest rate of complete response (69 out of 163 (42%) vs other sites 71 out of 404 (18%), P<0.0001). Delayed response post first scan was seen in 2 out of 37 (5%) deemed progressive (PD) by RECIST and 2 out of 14 (14%) deemed PD by irRC. Modified CHOI criteria showed response of 38% (14 out of 37). Change in tumour size and density on first follow-up assessment was associated with OS with each 1000 mm 2 increase in tumour size from baseline increasing the hazard of dying by 25.9% (HR=1.259, (95% CI=1.116-1.420), P=0.0002). Similarly, each 20HU increase in density increased the HR by 15% (HR=1.15, (95% CI 1.045-1.260), P=0.004). Response defined by any criteria had superior OS (CHOI P=0.0084; mCHOI P=0.0183; irRC P<0.0001 and RECIST P=0.0003).Conclusions:Response by any criterion was prognostic. Novel patterns of response and changes on treatment in tumour density suggest complex anti-tumour responses to immunotherapy.
|
||||||||||
2015 |
Gedye C, Boyle FM, 'Optimising treatment for Australian melanoma patients can save taxpayers millions of dollars annually', The Medical journal of Australia, 202 130 (2015) [C3]
|
||||||||||
2015 |
Gedye C, Boyle FM, 'Optimising treatment for Australian melanoma patients can save taxpayers millions of dollars annually', MEDICAL JOURNAL OF AUSTRALIA, 202 I-I (2015)
|
||||||||||
2015 |
Gedye C, van der Westhuizen A, John T, 'Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities.', Intern Med J, 45 696-701 (2015) [C1]
|
||||||||||
2014 |
Gedye CA, Hussain A, Paterson J, Smrke A, Saini H, Meyer M, 'Correction: Cell surface profiling using high-throughput flow cytometry: A platform for biomarker discovery and analysis of cellular heterogeneity', PLoS ONE, 9 (2014)
|
||||||||||
2014 |
Naert K, Al Habeeb A, Gedye C, Ghazarian D, 'Targeted therapy in melanoma: The era of personalized medicine', Diagnostic Histopathology, (2014) [C1] Malignant melanoma is the most aggressive of all cutaneous tumours, with over 76, 000 new cases and 9700 deaths estimated for 2014 in the United States.1 In Canada, both the incid... [more] Malignant melanoma is the most aggressive of all cutaneous tumours, with over 76, 000 new cases and 9700 deaths estimated for 2014 in the United States.1 In Canada, both the incidence and mortality of melanoma are increasing, with a risk of developing melanoma being 1 in 59 for men and 1 in 73 for women.2 The incidence of melanoma is higher in Australia, with a risk of 1 in 14 for males and 1 in 23 for females to age 85 reported for 2009.3 Although early melanoma can be managed surgically, until recently there have been few advances in the treatment of advanced melanoma. However, with the introduction of molecular targeted therapies, the landscape of melanoma treatment has changed dramatically in the past five years, resulting in improved survival rates for patients with metastatic disease. In this review, we will discuss the molecular basis and implementation for some of these novel treatments with particular emphasis on BRAF and BRAF inhibitors.
|
||||||||||
2013 |
Sompallae R, Hofmann O, Maher CA, Gedye C, Behren A, Vitezic M, et al., 'A comprehensive promoter landscape identifies a novel promoter for CD PROM1 is the gene encoding prominin-1 or CD133, an important cell surface marker for the isolation of both normal and cancer stem cells. PROM1 transcripts initiate at a range of t... [more] PROM1 is the gene encoding prominin-1 or CD133, an important cell surface marker for the isolation of both normal and cancer stem cells. PROM1 transcripts initiate at a range of transcription start sites (TSS) associated with distinct tissue and cancer expression profiles. Using high resolution Cap Analysis of Gene Expression (CAGE) sequencing we characterize TSS utilization across a broad range of normal and developmental tissues. We identify a novel proximal promoter (P6) within CD133+ melanoma cell lines and stem cells. Additional exon array sampling finds P6 to be active in populations enriched for mesenchyme, neural stem cells and within CD133+ enriched Ewing sarcomas. The P6 promoter is enriched with respect to previously characterized PROM1 promoters for a HMGI/Y (HMGA1) family transcription factor binding site motif and exhibits different epigenetic modifications relative to the canonical promoter region of PROM1.© 2013 Sompallae, Hofmann, Maher, Gedye, Behren, Vitezic, Daub, Devalle, Caballero, Carninci, Hayashizaki, Lawlor, Cebon and Hide.
|
||||||||||
Show 58 more journal articles |
Conference (48 outputs)
Year | Citation | Altmetrics | Link | ||
---|---|---|---|---|---|
2020 |
Pandey D, Mweempwa A, Di Iulio J, Gedye C, 'Best of the Best Orals', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020)
|
||||
2020 | Wefel JS, Won M, Lassman A, Stern Y, Wang T, Aldape K, et al., 'NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM', NEURO-ONCOLOGY, ELECTR NETWORK (2020) | ||||
2020 | Mallesara G, Kumar M, Nordman I, Mandaliya H, Ludbrook J, Day F, et al., 'Supervised exercise program in lung cancer patients on curative intent chemoradiation', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020) | ||||
2020 | Blanchard G, Bonaventura A, Dafters N, Day F, Gedye C, Gildenhuys J, et al., 'The impact of integrating an oncology nurse practitioner into an acute care hospital emergency department: An Australian tertiary cancer centre experience.', JOURNAL OF CLINICAL ONCOLOGY (2020) | ||||
2020 | Grimison PS, Stockler MR, Kirby A, Walsh A, Lintzeris N, Cheung Y, et al., 'Results of crossover phase II component of randomized placebo-controlled trial evaluating oral THC/cannabis extract for refractory chemotherapy-induced nausea and vomiting (CINV).', JOURNAL OF CLINICAL ONCOLOGY (2020) | ||||
2019 | Retz M, Merseburger AS, Loriot Y, James N, Choy E, Castellano D, et al., 'Primary results from SAUL, a prospective multinational single-arm study of Atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract', ONCOLOGY RESEARCH AND TREATMENT (2019) | ||||
2018 |
Mersiades A, Tognela A, Haber P, Stockler MR, Lintzeris N, McGregor I, et al., 'Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)', JOURNAL OF CLINICAL ONCOLOGY (2018)
|
||||
2017 |
Rowe C, King S, Tolosa J, Paul J, Gedye C, Smith R, 'Overexpression of the Sodium-Iodide Symporter in thyroid cancer co-existing with Graves disease', Perth, Western Australia (2017)
|
||||
2017 |
Rowe C, Tolosa Gonzalez JT, Faulkner S, Paul JW, Gedye C, McGrath S, et al., 'The precursor for nerve growth factor (proNGF) is detectable in the rinse of fine needle aspiration biopsy of thyroid cancer', Boston, Massachussetts (2017)
|
||||
2015 |
Laegdsgaard P, Nielsen S, Koegelenberg A, Goode S, Thorne R, Lund D, et al., 'A NEW VENTURE FOR THE HUNTER CANCER BIOBANK-ESTABLISHMENT OF SEQUENTIAL BLOOD COLLECTION FOR BRAIN CANCER RESEARCH', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
||||
2014 |
Gedye C, Kurban G, Gallie BL, Leveridge MJ, Musquera M, Morales C, et al., 'Surgical ischemia and detection of clear cell renal cell carcinoma biomarkers', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2014)
|
||||
2014 |
Gedye C, Sirskyj D, Lobo NC, Hyatt E, Evans A, Finelli A, et al., 'Essential experimental steps and estimates of renal carcinoma initiating cells', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2014)
|
||||
2014 |
Gedye C, Sirskyj D, Hyatt E, Lobo N, Lourenco C, Evans A, et al., 'MESENCHYMAL DIFFERENTIATION PROGRAMS GOVERN VHL-MUTANT CLEAR CELL RENAL CANCER BIOLOGY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
||||
2014 |
Koegelenberg AM, Dean S, Nielsen S, Carroll R, Mellon A, Surgeons G, et al., 'THE IMPACT OF INTEGRATING SYSTEM CHANGES INTO ROUTINE HEALTHCARE PRACTICES VIA MODIFICATION OF EXISTING PROCESSES; A LOOK AT BIOBANKING CONSENT IN THE HUNTER REGION', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
||||
2013 |
Gedye C, Sirskyj D, Lobo NC, Evans A, Fleshner NE, Robinette M, et al., 'VHL-mutant renal cell carcinomas contain cancer cells with mesenchymal phenotypes', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2013) [E3]
|
||||
2013 | Davidson A, Quirk J, Gedye C, Browning J, Bolton D, Davis I, 'Differential cancer/testis antigen expression in colony forming bladder cancer cell populations', BJU INTERNATIONAL, Melbourne, AUSTRALIA (2013) [E3] | ||||
Show 45 more conferences |
Grants and Funding
Summary
Number of grants | 24 |
---|---|
Total funding | $14,002,925 |
Click on a grant title below to expand the full details for that specific grant.
20194 grants / $2,743,793
MAGMA Multi-Arm GlioblastoMa Australasia$2,421,993
Brain cancer is a challenging health problem to face. Brain cancers like glioblastoma and astrocytoma are (perhaps mercifully) relatively uncommon, so people suffering brain cancer are often treated in many different hospitals. It can be hard to coordinate studies and clinical trials between different hospitals and doctors, and so it can be more difficult to study and test ideas to improve treatments. We are extremely excited to be developing a new clinical trial for people with brain cancer, to be run by the Cooperative Trials Group
for Neuro-Oncology (COGNO) trying to reach out to as many patients and their doctors as possible across Australia (and hopefully in the future New Zealand too).
The clinical trial is called MAGMA (standing for Multi-Arm GlioblastoMa Australasia). The clinical trial aims to make small changes in the way that we use our existing treatments for brain cancer; small changes that we hope will have big impacts for future patients. Some clinical trials test new drugs or new treatments; these sometimes deliver a benefit but as often as not they can’t beat the standard treatment. MAGMA fills the gap in the other direction; when we have a treatment that we know does help, we seek to make it work better, aiming to keep people feeling well for longer.
The first two ideas (in the first two arms of the study) that we are testing in MAGMA are based around the chemotherapy drug commonly used in brain cancer, temozolomide. The standard treatment uses this chemotherapy drug daily with radiation treatment and then monthly for six months after radiation finishes.
Our two questions are 1) what if we started the chemotherapy as soon as possible after surgery, before the radiation starts? And 2) what if we carried on the monthly chemotherapy for as long as it seemed to be working – or can we take a break and start it again later if/when needed?
These kinds of simple questions have led to significant improvements in other cancers, and have changed how we recommend treatment to people with prostate cancer, ovarian cancer and other cancers.
We are incredibly grateful for the support of the Mark Hughes Foundation who are supporting the Australian Brain Cancer Mission that has provided the funding to support MAGMA through the Medical Research Future Fund.
Funding body: Cancer Australia
Funding body | Cancer Australia |
---|---|
Project Team | Gedye C, Nowak A, Hovey E, Koh E-S, Harrup R, Parkinson J, Barnes E, Jeffree R |
Scheme | Rare Disease and Rare Cancers |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2024 |
GNo | |
Type Of Funding | C1300 - Aust Competitive - Medical Research Future Fund |
Category | 1300 |
UON | N |
New horizons. Therapeutic applications for medicinal cannabis in the treatment of brain cancer.$190,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Matt Dun, Dr Kelly McKelvey, Doctor Adjanie Patabendige, Doctor Ameha Woldu, Doctor Mengna Chi, Doctor Craig Gedye |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2019 |
Funding Finish | 2020 |
GNo | G1900131 |
Type Of Funding | C3120 - Aust Philanthropy |
Category | 3120 |
UON | Y |
COgnitive impairment in People with glioma and distress in their INformal care-Givers: feasibility and acceptability of a systematic screening process and structured referral process$100,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Liz Fradgley, Professor Christine Paul, Conjoint Professor Peter Schofield, Doctor Craig Gedye, Conjoint Professor Stephen Ackland, Associate Professor Helen Wheeler, Ms Marina Kastelan, Sandy Nixon, Mrs Alisha Gooley, Associate Professor Fiona Schulte |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2019 |
Funding Finish | 2021 |
GNo | G1801423 |
Type Of Funding | C3112 - Aust Not for profit |
Category | 3112 |
UON | Y |
Heterogeneity in Cancer$31,800
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Craig Gedye |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1900542 |
Type Of Funding | C3120 - Aust Philanthropy |
Category | 3120 |
UON | Y |
20186 grants / $2,062,198
UNICAB: A phase II trial of single agent cabozantinib in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy (ANZUP 1802)$1,173,201
Cabozantinib is an anti-cancer drug that works by blocking cancer cell growth. Cabozantinib has previously been used in the treatment of many cancers, including clear cell kidney cancer and thyroid cancer. However, it has not been tested in people with non-clear cell kidney cancer.
About 48 participants with non-clear cell kidney cancer are expected to participate in this study, from Australia.
Funding body: Ipsen Pty Ltd
Funding body | Ipsen Pty Ltd |
---|---|
Project Team | Pook D, Gedye C, Harris C, Davis I, Krieger L, McJannett M. |
Scheme | Research Project |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2023 |
GNo | |
Type Of Funding | C3211 - International For profit |
Category | 3211 |
UON | N |
Stereotactic Ablative Radiotherapy (SABR) as a New Precision Treatment Option in Kidney Cancer (ASSOCIATE INVESTIGATOR)$589,000
Associate Investigator
Funding body: Cancer Australia
Funding body | Cancer Australia |
---|---|
Project Team | Siva S, Kron T, Martin J, Christie D, Lawrentschuk N, De Abreu Lourenco R, Carmichael A, Vanneste B, Gedye C, Mathias B, Hofman M, Brook N, Lo S. |
Scheme | Priority-driven Collaborative Cancer Research Scheme |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2021 |
GNo | |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | N |
A new biomarker to predict response to PARP inhibitors in glioblastoma$100,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Doctor Craig Gedye |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1801446 |
Type Of Funding | C3112 - Aust Not for profit |
Category | 3112 |
UON | Y |
Investigating a new class of drugs for the treatment of brain cancer$99,997
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Doctor Craig Gedye |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1701638 |
Type Of Funding | C3120 - Aust Philanthropy |
Category | 3120 |
UON | Y |
The Virtual Biobank$50,000
Funding body: Woodend Foundation
Funding body | Woodend Foundation |
---|---|
Project Team | Doctor Craig Gedye, Professor Marjorie Walker, Doctor Simon King, Doctor Bill Pascoe, Ms Cassandra Griffin, Dr Jamie Flynn, Dr JAMIE Flynn, Antony Martin, William Palmer |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2019 |
GNo | G1701611 |
Type Of Funding | C3112 - Aust Not for profit |
Category | 3112 |
UON | Y |
EnzAdapt: feasibility, acceptability and safety of adaptive dosing of enzalutamide in men with metastatic castrate-resistant prostate cancer$50,000
When prostate cancer spreads, injections that suppress the male hormone testosterone can control the cancer for some time, but it almost always starts to grow again later. Hormone tablets to block testosterone on top of the injections can regain control of the cancer, but again, only for a limited time of about one year. Cancers grow like weeds; some of the cancer cells can be controlled by weedspray but other parts of the cancer aren’t affected and can flourish. These vulnerable and resistant cells of the cancer are often holding each other in balance; and when a treatment is used it can favour one group of cancer cells over another. This trial is designed to test the idea of taking breaks off taking hormone tablets, using them for long enough to control the cancer, but then stopping and saving them up until later to treat the cancer again (and again… and hopefully again and again). While every man’s cancer is predicted to eventually become resistant to hormone treatments, using hormone tablets in a sparing and cunning way is hoped to spread the benefit over a longer period of time, without more side-effects. Very early reports with other drugs support this idea; this will be the first trial testing this idea with enzalutamide (Xtandi). If this idea proves to be sound, it may improve the lives and survival of men with prostate cancer.
Funding body: Below the Belt Research Fund
Funding body | Below the Belt Research Fund |
---|---|
Project Team | Drs Mandaliya, Lynam, Mallesara, Bonaventura, Abell, Livshin, CelliMarchett |
Scheme | ANZUP Below the Belt Research Fund |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | C3112 - Aust Not for profit |
Category | 3112 |
UON | N |
20173 grants / $5,704,145
KeyPAD$2,413,500
The commonest kind of advanced kidney cancer is called clear cell kidney cancer. Immune therapies have been shown to be effective in about a quarter of patients with advanced clear cell kidney cancer after the standard tablet treatment has failed. This study will test if a drug (denosumab) usually used to treat osteoporosis (thinning of the bones) or cancer that has spread to the bones, can be added to the immune therapy to increase the ability of the body’s immune system to attack kidney cancer cells. This study is designed to assess the effects and safety of the combination of two drugs; pembrolizumab and denosumab. All participants on the trial will receive both treatments. Blood and cancer samples will be collected from each patient to better understand who has benefited and who has been failed by the treatment combination.
Funding body: MSD Australia and Amgen Australia
Funding body | MSD Australia and Amgen Australia |
---|---|
Project Team | ANZUP Cancer Trials Group |
Scheme | Investigator-initiated research project |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2020 |
GNo | |
Type Of Funding | External |
Category | EXTE |
UON | N |
UNISoN; Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab In Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602; CA209-718)$1,681,800
In this clinical trial ANZUP will test whether new immune treatments can help people with rare kidney cancer (‘non-clear cell’ cancer). Non-clear cell represents approximately 25% of people with kidney cancer; and because it is rare there are no treatments currently reimbursed in Australia.
The UNISoN trial will test immune treatments in two different ways; firstly we will find out how well one immune treatment (nivolumab) works alone. If this is unhelpful by itself, then people can continue taking nivolumab but also add in a 2nd immune treatment (ipilimumab). We will discover how many people will benefit from one drug alone, and by doing detailed laboratory testing of people’s cancer samples, hope to also learn who will only benefit from taking both treatments together.
Nivolumab and ipilimumab have been used alone or together in many cancers, so the side-effects are well known and should be manageable. Immune treatments help some people with cancer, especially those with melanoma, common (clear cell) kidney cancer, lung and bladder cancer. Unfortunately they are much less effective in other cancers (like pancreas, prostate and brain cancers). Nivolumab and ipilimumab have not been tested in people with non-clear cell kidney cancers, so ANZUP is delighted to ask this question, and hope to help people with this rare disease.
Funding body: BMS Australia
Funding body | BMS Australia |
---|---|
Project Team | ANZUP Cancer Trials Group |
Scheme | Investigator initiated research project |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2021 |
GNo | |
Type Of Funding | External |
Category | EXTE |
UON | N |
2:1 Randomised Phase II Study of NivolUmab and Temozolomide vs Temozolomide in Methylated newly diagnosed Elderly Glioblastoma (NUTMEG) ASSOCIATE INVESTIGATOR$1,608,845
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Khasraw M, Rosenthal M, McDonald K, Ashley D. |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2017 |
Funding Finish | 2022 |
GNo | |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | N |
20162 grants / $1,753,049
Start-Up activities with or without a pilot and definitive randomised double-blind placebo-controlled trial of oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting$1,750,000
Does cannabis help people taking chemotherapy? There is anecdotal evidence but this clinical trial will provide a definitive answer.
Introduction Chemotherapy-induced nausea and vomiting (CINV) remains an important issue for patients receiving chemotherapy despite guideline-consistent antiemetic therapy. Trials using delta-9-tetrahydrocannabinol-rich (THC) products demonstrate limited antiemetic effect, significant adverse events and flawed study design. Trials using cannabidiol-rich (CBD) products demonstrate improved efficacy and psychological adverse event profile. No definitive trials have been conducted to support the use of cannabinoids for this indication, nor has the potential economic impact of incorporating such regimens into the Australian healthcare system been established. CannabisCINV aims to assess the efficacy, safety and cost-effectiveness of adding TN-TC11M, an oral THC/CBD extract to guideline-consistent antiemetics in the secondary prevention of CINV.
Methods and analysis The current multicentre, 1:1 randomised cross-over, placebo-controlled pilot study will recruit 80 adult patients with any malignancy, experiencing CINV during moderate to highly emetogenic chemotherapy despite guideline-consistent antiemetics. Patients receive oral TN-TC11M (THC 2.5mg/CBD 2.5 mg) capsules or placebo capsules three times a day on day −1 to day 5 of cycle A of chemotherapy, followed by the alternative drug regimen during cycle B of chemotherapy and the preferred drug regimen during cycle C. The primary endpoint is the proportion of subjects attaining a complete response to CINV. Secondary and tertiary endpoints include regimen tolerability, impact on quality of life and health system resource use. The primary assessment tool is patient diaries, which are filled from day −1 to day 5. A subsequent randomised placebo-controlled parallel phase III trial will recruit a further 250 patients.
Funding body: NSW Health
Funding body | NSW Health |
---|---|
Project Team | Grimison P, Haber P, Stockler M, Lintzeris N, Simes R, McGregor I, Olver I, Allsop D, Gedye C, Kirby A |
Scheme | Health Administration Corporation , NSW |
Role | Investigator |
Funding Start | 2016 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | Aust Competitive - Non Commonwealth |
Category | 1NS |
UON | N |
Bringing CLARITY to Brain Cancer$3,049
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Dr JAMIE Flynn, Doctor Craig Gedye |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2016 |
Funding Finish | 2016 |
GNo | G1600967 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
20155 grants / $687,675
Advanced Technical Support for Oncology Single Cell Analysis Technologies$300,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Laureate Professor Rodney Scott, Professor Xu Dong Zhang, Professor Hubert Hondermarck, Conjoint Professor Stephen Ackland, Doctor Craig Gedye, Professor Pradeep Tanwar, Doctor Chen Chen Jiang, Associate Professor Matt Dun, Professor Paul de Souza, Associate Professor Kevin Spring, Dr Tao Liu |
Scheme | Research Infrastructure Grants |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2018 |
GNo | G1500824 |
Type Of Funding | C2210 - Aust StateTerritoryLocal - Own Purpose |
Category | 2210 |
UON | Y |
The Hunter Cancer Biobank (HCB): Maximising community value through validation, annotation and distribution throughout NSW$300,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Professor Marjorie Walker, Conjoint Professor Stephen Ackland, Laureate Professor Rodney Scott, Emeritus Professor John Forbes, Professor Xu Dong Zhang, Professor Pradeep Tanwar, Associate Professor Nikola Bowden, Doctor Craig Gedye, Doctor James Lynam, Associate Professor Kelly Kiejda, Doctor Jennette Sakoff, Mr Loui Rassam, Dr Tara Roberts, Professor Soon Lee, Dr Betty Kan |
Scheme | Research Infrastructure Grants |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2018 |
GNo | G1500825 |
Type Of Funding | C2210 - Aust StateTerritoryLocal - Own Purpose |
Category | 2210 |
UON | Y |
Destroying kidney cells that evade current treatments$46,000
Funding body: Kidney Health Australia
Funding body | Kidney Health Australia |
---|---|
Project Team | Doctor Craig Gedye, Associate Professor Nikola Bowden, Laureate Professor Rodney Scott |
Scheme | Medical Research Project Grants |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1401048 |
Type Of Funding | C3112 - Aust Not for profit |
Category | 3112 |
UON | Y |
BAALC - a novel target for the development of new treatments for brain cancer.$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Doctor Craig Gedye |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1600225 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Too Much of a Good Thing: Application for a triple-gas incubator to allow cell culture under normal conditions$16,675
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Craig Gedye, Laureate Professor Rodney Scott, Associate Professor Nikola Bowden, Professor Simon Keely, Associate Professor Kathryn Skelding |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1500730 |
Type Of Funding | C3120 - Aust Philanthropy |
Category | 3120 |
UON | Y |
20143 grants / $787,065
The Virtuous Circle: A Living Brain Cancer BioBank$331,393
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Laureate Professor Rodney Scott, Doctor Craig Gedye, Professor Marjorie Walker |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2018 |
GNo | G1401406 |
Type Of Funding | C3120 - Aust Philanthropy |
Category | 3120 |
UON | Y |
High Throughput Image Capture Platform for Translational Cancer Research$282,614
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Conjoint Professor Stephen Ackland, Laureate Professor Rodney Scott, Emeritus Professor John Forbes, Professor Xu Dong Zhang, Professor Marjorie Walker, Professor Hubert Hondermarck, Doctor Craig Gedye, Doctor Rick Thorne, Mr Loui Rassam, Doctor Stephen Braye |
Scheme | Research Equipment Grant |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1400626 |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | Y |
Is Renal Cell Carcinoma Driven by "Cancer Stem Cells"?$173,058
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Craig Gedye |
Scheme | Training (Postdoctoral) Fellowships - C.J. Martin Biomedical Fellowships (Overseas) |
Role | Lead |
Funding Start | 2014 |
Funding Finish | 2015 |
GNo | G1400027 |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | Y |
1 grants / $265,000
Embedding patient tissue banking consent into routine clinical practice: To maximize state-wide consent and enable a patient-led approach to tissue banking$265,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Laureate Professor Rodney Scott, Doctor Craig Gedye, Professor Christine Paul, Assoc. Prof Nicholas Hawkins, Associate Professor Deborah Marsh, Professor Phil Crowe |
Scheme | Community of Practice Program |
Role | Investigator |
Funding Start | |
Funding Finish | |
GNo | G1400792 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Research Collaborations
The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.
Country | Count of Publications | |
---|---|---|
Australia | 81 | |
Canada | 31 | |
United States | 24 | |
Germany | 14 | |
United Kingdom | 14 | |
More... |
News
Study using new tools to unlock secrets of immune cells in cancer
May 25, 2017
Expanding the horizons of brain cancer research
October 13, 2015
More flexibility needed in melanoma treatment
February 16, 2015
Brain cancer biobank
October 29, 2014
Dr Craig Gedye
Position
Conjoint Associate Professor
School of Medicine and Public Health
Faculty of Health and Medicine
Contact Details
craig.gedye@newcastle.edu.au |